Clinical Trial Search

Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants

Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants

Primary: Overall Response Rate (Confirmed) — 1; 1 Participants

Primary: Overall Survival — 13.43; 7.62 months

Primary: Number of Participants With an Objective Response — 0; 0; 0; 0 Participants

Primary: Dose Escalation Phase: Maximum Tolerated Dose (MTD) — 6; 40; 9; 7 milligrams (mg)

Primary: To Determine the Safety and Tolerability of NGM120 in Subjects — 1; 6; 6; 17 Participants

Primary: Non-progression Rate (NPR) at 18 Weeks — 26.8; 44.4; 29.6; 40.0 percentage of participants

Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg

Primary: Safety and Tolerability Measured by Assessing Serious Adverse Events (SAEs)and Adverse Events (AEs) — 1; 3; 2; 2 Participants

Primary: Number of Participants With Bone Bio-marker Response — 13; 9; 8 Participants

Primary: Overall Response Rate (ORR) — 5.6; 0.0; 11.3; 14.3 percentage of participants

Primary: Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases) — 0…

Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 2 participants

Primary: Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Drug-Related AEs, Deaths, Discontinuation of Study Drug Due to AE, Dose-Limiting…

Primary: Dose Limiting Toxicity — 0; 0; 0; 0 Participants

Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…

Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths — 4; 3; 3; 3 Participants

Primary: Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer. — 0; 3 Participants

Primary: Objective Response Rate ( ORR ) — 5.6; 0.0; 0.0; 11.9 Percentage of Participants — p=0.0309

Primary: Overall Response Rate (ORR) in the Anaplastic Thyroid Cancer (ATC) Cohort — 56; 56; 53; 53 Percentage of Participants

Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient

Primary: Number of Participants Experienced Dose Limit Toxicities (DLT) — 0; 0 Participants

Primary: Number of Participants Experiencing Dose Limiting Toxicities — 0; 1; 7 Participants

Primary: Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration — 0; 0; 0; 0 Number of DLTs

Primary: Changes in Phospho-Chk1 Levels in Biopsy Specimens — 156; 196; 89; 84 percent change

Primary: The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies — 0; 2; 4 Events

Primary: Association of Baseline C11-AMT PET SUV Max Value With Objective Response — 6; 6; 1; 13 Participants — p=0.08

Primary: Percentage of Participants With PSA50 Response — 2 Participants

Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants